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Abstract 
Colorectal cancer (CRC) is the most commonly diagnosed cancer affecting both men and 
women in Australia. The Epidermal Growth Factor Receptor (EGFR) plays an important role in 
the development and progression of CRC. EGFR regulates a number of essential cellular 
processes including proliferation, migration, differentiation and survival however the 
overexpression of EGFR is a major driver of CRC tumourigenesis. Numerous studies have 
demonstrated that there is a strong association between a high carbohydrate and high fat 
diet (HCHF), EGFR expression and the tumourigenesis of CRC. One of the activators of EGFR 
signalling is A disintegrin and metalloprotease domain 17 (ADAM17) and this protein has also 
been implicated in high fat diet induced CRC. One of ADAM17’s roles is the proteolytic 
cleavage of EGFR activating ligands including the transforming growth factor alpha (TGFα).  
Curcumin has demonstrated promising anti-inflammatory, antineoplastic, antioxidant and 
chemopreventative properties in the colon and has been shown to suppress the growth of 
colon cancer cells in animal models and human cell culture. The effectiveness of curcumin in 
reducing the expression of CRC biomarkers caused by a HCHF diet has not yet been 
investigated but may prove to be an effective strategy for preventing CRC.  
This study provided evidence that a HCHF diet significantly increases the mRNA expression of 
the CRC biomarkers EGFR, ADAM17 and TGFα in the distal colon tissue obtained from rats fed 
a HCHF diet compared to those fed a normal corn starch diet. Furthermore, it demonstrated 
that the effects of these changes could be prevented by supplementing the HCHF diet with 
100 mg/kg body mass of curcumin. A preliminary experiment also found that the molecular 
changes that occurred in response to the HCHF diet could be driven by the aberrant 
expression of epigenetic modifying enzymes. Understanding the mechanisms by which diet 
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regulates tumourigenic changes in the colon is vitally important as diet is modifiable and may 
be a crucial target for preventing high fat diet induced CRC or at least reducing risk. 
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Glossary  
Adenocarcinoma: a malignant tumour formed in the glandular structures in epithelial tissue 
Angiogenesis: the process in which new blood vessels are formed  
Biomarker: a naturally occurring molecule, gene or characteristic by which a particular 
pathological or physiological process or disease can be identified  
Cytokine: A small protein released by cells that exerts particular effect on interactions 
between cells or on cell behaviour.  
Dimierisation: a chemical reaction in which two identical molecular entities react to form 
one single dimer  
Differentiation: process by which cells or tissue change from relatively generalised to highly 
specialised during development  
Epigenetic: relating or arising from non-genetic influences on gene expression  
Epimutation: A heritable change in gene expression that does not impact actual base pair 
sequence of DNA 
Histone: any group of five small basic proteins occurring in the nucleus of eukaryotic cells 
that organise DNA strands into nucleosomes by forming molecular complexes around which 
DNA winds.  
Homodimer: A protein made of paired identical polypeptides 
Heterodimer: a protein comprised of two polypeptide chains differing in composition in the 
order, number or kind of amino acid residues 
Hypermutation: process by which mutations are occurring at a higher frequency then 
expected 
Hyperplastic: an abnormal increase in the number of cells in an organ or tissue with 
consequent enlargement 
Knock-down/out: genetic technique that leads to gene becoming inoperable 
Neoplastic: relating to neoplasm which is characterised as uncontrolled growth of abnormal 
tissue 
Phosphorylation: The transferring of phosphoryl group from a donor to the 
recipient molecule 
Polyp: a small clump of cells protruding from the mucous membrane of the colon 
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Polyphenol: a compound containing more than one phenolic hydroxyl group  
Post- translational modification: processes occurring after translation of a polypeptide, that 
are often needed to generate a fully functional polypeptide. modifications include the 
addition or removal of functional groups such as acetyl, methyl or phosphate group to the n-
terminal tail of histones 
 
Proliferation: rapid multiplication of cells  
Tumourigenesis: process of tumour formation  
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 Chapter 1: Introduction and Literature Review 
1.1 Cancer and tumourigenesis  
Cancer is a disease characterised by the uncontrolled proliferation of abnormal cells which 
can invade into surrounding tissue layers and metastasise to distant tissues via the blood and 
lymphatic systems (Bardhan & Liu 2013). The proliferation of normal cells is tightly regulated 
via a balance between both growth promoting and growth supressing signals, so that 
proliferation only occurs when required (for example in tissue repair and growth) (Sa & Das 
2008). Tumourigenesis is the process whereby cells accumulate DNA mutations or 
epimutations that stimulate growth promoting signals and/or inhibit growth suppressing 
signals even when cells have experienced DNA damage. These DNA mutations may be 
germline (occurring in all of the body’s cells) mutations in genes that usually control the cell 
cycle such as Tumour Protein 53 (TP53) or DNA repair such as Breast Cancer 1 (BRCA1) or can 
be sporadic mutations in these genes arising only in the precursor primary tumour cells. 
Mutations alter the DNA sequence of the gene and can change the structure and/or function 
of the transcribed protein. Epimutations do not actually change the DNA sequence of genes 
but influence their expression by increasing or decreasing the methylation of their promoters.  
Epimutations that can drive tumourigenesis occur in genes that control growth factor 
signalling, DNA damage repair, cell migration and invasion. Over time, the accumulation of 
mutations and/or epigenetic mutations in tumourigenic cells further stimulates the tumour 
to degrade and migrate into surrounding tissue and in some instances, cells from the tumour 
can invade into blood and lymphatic vessels and spread to distant parts of the body forming 
secondary or metastatic tumours   (Al-Sohaily et al. 2012; Lahtz & Pfeifer 2011).  
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1.2 Colorectal cancer development and progression  
The incidence of colorectal cancer (CRC) is increasing globally with the highest incidence 
occurring in Australia (as illustrated in Figure 1) (Torre et al. 2015). CRC is now the most 
commonly diagnosed cancer affecting both men and women in Australia (Australian Institute 
of Health and Welfare, AIHW, 2015). In 2011 a total of 15,151 new cases were diagnosed in 
Australia and 17,070 new cases were projected to be diagnosed in 2016 (AIHW, 2015). 
Patients diagnosed with metastatic CRC currently have a five year survival rate of less than 
15% (Pabla et al. 2015). CRC occurs in both hereditary and sporadic forms, with sporadic forms 
most strongly associated with lifestyle factors such as consuming a diet that is high in simple 
carbohydrates, high in animal fats and low in dietary fibre as well as physical inactivity (Schulz 
et al. 2014). A poor diet combined 
with physical inactivity can lead to 
changes in metabolism which has 
consequences at both a cellular and 
molecular level, potentially driving 
CRC tumourigenesis (Hagland et al. 
2013). Understanding the 
mechanisms by which diet regulates 
tumourigenic changes in the colon is 
vitally important as diet is 
modifiable and may be a crucial 
target for preventing colorectal 
cancer or at least reducing the risk of it occurring.  
Figure 1: Global colon cancer statistics demonstrating the 
highest incidence in Australia and New Zealand (Torre et al. 
2015). 
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CRC is caused by the accumulation of genetic and/or epigenetic mutations within a population 
of epithelial cells in the colon or rectum.  This drives these cells to transform into an 
adenocarcinoma (Bardhan & Liu 2013). CRC usually progresses slowly with the disease 
typically arising from a precursor legion such as a benign polyp (hyperplastic polyp) within the 
epithelial lining of the colon or rectum. As mutations continue to occur there is an increased 
risk of the polyp transforming into a premalignant adenoma (tubular adenoma) which can 
then progress into malignant adenocarcinoma, which if untreated can metastasise to distant 
sites such as liver and lung tissue (as illustrated in Figure 2) (Bardhan & Liu 2013; Hagland et 
al. 2013). The development of genetic instability is a key driver of CRC tumourigenesis and the 
three main phenotypes/pathways in which it occurs are chromosomal instability (CIN), 
microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP).  The majority 
of sporadic CRC arises as a result of CIN. The CIN phenotype is characterised by genetic 
alterations such as insertions, inversions, deletions and rearrangements within the 
chromosome (Lengauer et al. 1997), all of which cause changes in gene expression. The exact 
mechanisms causing CIN are not fully understood, however genes believed to be implicated 
in the development of CIN are involved in cell cycle checkpoint, mitotic spindle check point, 
chromosome segregation and condensation and sister chromatid cohesion (Hagland et al. 
2013).  CIN tumours have been shown to display a number of commonly mutated genes 
implicated in the pathogenesis of CRC including adenomatous polyposis coli (APC), Kirsten Rat 
Sarcoma Viral Oncogene Homolog (KRAS) and TP53 (Geigl et al. 2008). MSI accounts for 
approximately 15-20% of sporadic CRCs and are a result of epigenetic silencing of the MLH1 
gene and other genes involved in DNA mis-match repair and are commonly associated with 
the methylation of CpG islands. CIMP is characterised by changes in methylation patterns of 
promoter regions of a number of genes (Hagland et al. 2013). CpG islands are located in 
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promoter region of 50% of genes and therefore aberrant expression in these areas can have 
deleterious effects, with changes in methylation described as a major driver of 
tumourigenesis as it causes aberrant silencing or expression of genes that control tumour 
suppression, cell cycle activation and control, DNA repair and/or cell invasion (Kim & Deng 
2007). 
 
Figure 2: Development and progression of CRC from precursor lesion to distant metastasis 
(Hagland et al. 2013). 
 
1.3 Proximal versus distal colon cancer  
Until early this decade, CRC was treated as one disease, however recently it has become 
apparent that tumours arising in the proximal or right side colon commonly display a 
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molecular profile with mutations and epigenetic modifications that are different to those 
seen in distal or left side colon tumours (outlined in Figure 3). The progression of CRC is also 
site-specific with proximal tumours disseminating more commonly to abdominal viscera and 
lymph nodes whereas distal tumours commonly metastasise to the liver and chest wall 
(Missiaglia et al. 2014). Proximal tumours more commonly arise through hypermutation (the 
state in which a genetic mutation will occur at a higher rate than expected), MSI or CIMP 
pathway and a large proportion of them contain BRAF-mutations and lead to activation of the 
mitogen-activated protein kinase (MAPK) pathway (Missiaglia et al. 2014). This is a key 
signalling pathway involved in the regulation of normal cell proliferation, survival and 
differentiation (Roberts & Der 2007) as well as driving CRC tumourigenesis. Proximal tumours 
are reported to have a worse overall survival with a survival after relapse rate of only 1.3 years 
(Loupakis et al. 2015; Missiaglia et al. 2014). Distal tumours are commonly associated with 
the CIN pathway and overexpression of epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER2). Only approximately 13% of distal tumours are 
associated with BRAF mutations (Missiaglia et al. 2014). These tumours are associated with a 
more favourable outcome in terms of overall survival, progression-free survival and survival 
after relapse of 2.7 years (non-BRAF mutations) although distal tumours with BRAF mutations 
have the worst survival at 0.8 years (Loupakis et al. 2015). Recent research has shown that 
CRC is a heterogenic disease and therefore individual tumour mutation and gene expression 
profiles should be used to categorise patients into groups where they receive treatment 
approaches that will be most beneficial to the patient (Missiaglia et al. 2014).  
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Figure 3: Biological characteristics of proximal and distal tumours and their associated survival 
after relapse outcomes (Missiaglia et al. 2014). 
 
1.4 Colorectal cancer and diet  
Over the past decade, both epidemiological and molecular research studies have 
demonstrated a strong association between the so-called Western diet characterised by the 
increased consumption of foods that are typically high in animal fats particularly from red 
meat, protein and simple and low fibre carbohydrates with the incidence and development 
of CRC (Dougherty et al. 2009; Lee et al. 2008; Lipkin et al. 1999). A landmark study published 
in 1968 comparing the incidence of CRC amongst Japanese-American emigrants and Japanese 
living in America demonstrated considerably higher rates of CRC in the emigrants after two 
generations of living in the United States (Haenszel & Kurihara 1968). The authors of this study 
Colorectal Cancer
Proximal location 
(ascending and 
transverse)
Hypermutation and MSI
Hypermutation and CIMP
BRAF mutations
Activated MARK pathway
Outcome: SAR= 1.3 years
Distal location 
(descending)
CIN
EGFR and HER2/neu 
overpexression 
Outcome: 
Non BRAF mutation (87%) SAR= 2.7 years
BRAF mutation (13%) SAR= 0.8 years
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suggested that this pattern was a consequence of the emigrants changing from their 
traditional Japanese diet that is low in simple carbohydrates and low in fat to the Western 
diet and lifestyle, typified by a high simple carbohydrate and high fat diet and lower levels of 
physical activity (Haenszel & Kurihara 1968). More recent studies in human populations have 
also demonstrated that a diet high in animal fats increases the risk of CRC (Aleksandrova et 
al. 2014). Other studies have suggested that it is the obesity that arises from a high fat diet 
rather than the high fat diet itself that stimulates the development of CRC (Li et al. 2014; Liu 
et al. 2012).  
A number of rodent models have been used to investigate the effects of the Western diet in 
the development of CRC. These models stimulate CRC tumourigenesis using chemical 
carcinogens or genetic engineering approaches (Fujisawa et al. 2008; Qi et al. 2015) and then 
measure the effects of the high fat diet.  A recent review comparing various rodent models 
by Panchal and Brown (2010) reported that a diet high in simple carbohydrates as well as fat 
is more representative of the Western diet compared to a high fat diet alone and therefore 
recommended that this diet can better mimic Western diet-related diseases in rodents  
(Panchal & Brown 2010). 
 
1.5 Molecular pathways in CRC tumourigenesis 
The dysregulation of a number of molecular pathways has been implicated in CRC 
tumourigenesis, however the impact of a short-term diet high in both simple carbohydrates 
and animal fat on CRC development, in particular the CRC tumourigenesis biomarkers 
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epidermal growth factor receptor (EGFR), a disintegrin and metalloprotease domain 17 
(ADAM17) and transforming growth factor alpha (TGFα) has not been published.  
 
1.5.1 The role of EGFR 
It is well-established that EGFR plays a pivotal role in the development and progression of 
CRC. Since the discovery of EGF in 1962 and the subsequent identification of its receptor by 
Cohen et al (1962), numerous studies have reported its involvement in CRC. The 
overexpression of EGFR is a major driver of CRC, with overexpression of EGFR associated with 
up to 85% of CRC cases and generally accompanied by a poorer prognosis (Ellina et al. 2014).  
Overexpression of EGFR leads to increased cell proliferation and cell survival, both of which 
are hallmark characteristics of cancer.  
EGFR is a 170kDa transmembrane protein that harbours intrinsic protein tyrosine kinase 
activity. EGFR along with the human epidermal growth factor receptor 2 (HER2), human 
epidermal growth factor receptor 3 (HER3 or ErbB3) and human epidermal growth factor 
receptor 4 (HER4 or ErbB4) comprise the human epidermal growth factor receptor family of 
type 1 protein tyrosine kinases (Ellina et al. 2014). EGFR consists of two cysteine-rich domains 
that contain ligand binding regions on the extracellular domain. A single alpha-helical 
transmembrane domain connects the ligand-binding region to the intracellular receptor, 
which is comprised of three domains. The first domain acts as a site feedback attenuation by 
protein kinase C (PKC) and extracellular signal regulated kinases (ERK)-MAPK, the second 
domain is a tyrosine kinase domain and the third domain is a carboxyl-terminal tail. EGFR is 
found on all epithelial and stromal cells and is also expressed on glial and smooth cells (Pabla, 
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et al.  2015). Activation of EGFR is initiated by the binding of one or more of the seven peptide 
growth factors including EGF, TGF-α, heparin binding EGF-like growth factor (HB-EGF), 
amphiregulin, betacellulin, epiregulin and epigen (Schneider & Wolf 2009). Aberrant 
expression of EGFR and the prime natural ligands of EGF and TGF-α and have been implicated 
in driving CRC tumourigenesis (Ellina et al. 2014). The binding of ligand to the EGFR results in 
receptor dimerisation which leads to the formation of homodimers (both EGFR) and 
heterodimers (EGFR and HER2, HER3 or HER4) and triggers the intracellular activation of 
tyrosine kinase. The phosphorylation of intracellular pathways then occurs and induces the 
activation of multiple signal transduction pathways. The two major intracellular pathways 
that are activated by EGFR are the MAPK pathway and the phosphatidylinositol 3-kinase 
(PI3K) protein kinase B (AKT) pathway (see Figure 4). Both of these pathways lead to the 
subsequent activation of numerous transcription factors that stimulate cellular responses 
such as proliferation, migration, differentiation and survival (Ellina et al. 2014).  
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Figure 4: Signalling pathways initiated by the epidermal growth factor receptor (Yarom & 
Jonker 2011). 
 
EGFR signalling is also strongly implicated in the diet-induced tumourigenesis of CRC. EGFR 
knock-out studies conducted by Dougherty et al (2009) demonstrated that EGFR is required 
for dietary fat- induced tumour promotion. They compared rats with the wild type EGFR 
(EGFRwt) with rats with a genetically engineered waved-2 EGFR mutation (EGFRwa2), which 
caused a loss of 90% of EGFR function. The results of this study demonstrated that 31% of the 
EGFRwt mice fed a 20% fat diet developed CRC compared to 11.5% of EGFRwt mice fed a 5% 
fat diet, however the EGFR wa2 rats that were fed the same 20% fat diet as EGFRwt had 
significantly lower tumour incidence (Dougherty et al. 2009). Although there is compelling 
evidence that EGFR plays a major role in the development of CRC in response to a high fat 
diet, it still remains unclear as to what is driving the increase in EGFR signalling.  
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1.5.2 The role of ADAM17 
A number of studies have highlighted the involvement of ADAM17 in the activation of EGFR 
and consequently the tumourigenesis of CRC. ADAM17, also commonly referred to as the 
tumour necrosis factor alpha (TNF-) converting enzyme (TACE), is one of a number of ADAMs 
which are transmembrane proteins that cleave membrane-anchored proteins that control the 
release of soluble factors that activate key processes in cells such as proliferation and 
apoptosis (Nakagawa et al. 2009). An important function of ADAM17 is the activation of EGFR 
through the process of ectodomain shedding. Ectodomain shedding is the proteolytic removal 
of the extracellular domain of transmembrane proteins that are EGFR-activating ligands. 
ADAM17 regulates the release of growth factors and their receptors, cytokines, cell adhesion 
molecules and ectoenzymes and is implicated as an integrator of diverse signals that can 
potentially influence the control of tumourigenesis. A study by Blanchot-Jossic et al (2005) 
was the first to report that ADAM17 mRNA was upregulated in 90% of the human CRCs that 
they investigated compared to adjacent normal tissue. The study also demonstrated that 
EGFR was overexpressed in 77% of these tumours, therefore suggesting that the 
overexpression of both ADAM17 and EGFR may be inter-related. This concept is supported by 
the role in which ADAM17 plays in the activation of EGFR through the shedding of its ligands 
(Blanchot-Jossic et al. 2005). ADAM17 knockout studies by Nakagawa et al (2009) also support 
this hypothesis as ADAM17-deficient mice experienced perinatal death and demonstrated 
widespread epithelial defects, a similar phenotype to EGFR-deficient mice. Furthermore, the 
ADAM17-deficient mice also demonstrated diminished expression of EGFR compared to 
ADAM17 wildtype litter mates (Nakagawa et al. 2009).  Mutusfi et al (2016) has demonstrated 
the importance of ADAM17 in CRC tumourigenesis, with knockout studies involving the 
 | P a g e  
Amanda Dieckmann 
27 
targeted deletion of ADAM17 from colon epithelial cells leading to a significant reduction in 
tumour development (Mustafi et al. 2016). 
A recent study has also demonstrated a link between a diet high in fats and the 
overexpression of ADAM17. Matsui et al (2014) compared ADAM17-overexpressing 
transgenic (Tg) mice and wild type mice fed a high fat (60%) diet to reveal that overexpression 
of ADAM17 in the Tg mice led to an increase in TNF and macrophage-related cytokines and 
chemokines which are indicative of the inflammatory response that precedes obesity (Matsui 
et al. 2014).  Another recent study by Mustafi et al (2016) has shown that a high fat diet causes 
an increase in the expression of the ligand CXCL12 which upregulates expression of its 
receptor, CXCR4. The up-regulation of CXCR4 has a flow on effect that results in the up-
regulation of ADAM17, which leads to an increase in TGFα. As TGFα is one of the EGFR ligands, 
its up-regulation ultimately leads to overexpression of EGFR, which as already mentioned, is 
a major driver of CRC (Mustafi et al. 2016).  
Shimoda et al (2016) proposed that ADAM17 is the rate limiting factor controlling colon 
epithelial cell proliferation and differentiation by shedding diverse EGFR ligands which once 
bound to EGFR initiate a downstream signalling cascade that results in the stimulation of 
cellular proliferation and differentiation (Shimoda et al. 2016).  
 
1.6 Epigenetic modifications in CRC  
The role of epigenetic modification of the genome in CRC tumourigenesis has received a 
substantial amount of attention over the past two decades with recent research suggesting 
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that it plays a pivotal role. Epigenetic modifications of tumour suppressor or oncogenes have 
been strongly associated with pathogenesis of the CRC, with recent studies on the CRC 
epigenome demonstrating that these cells are riddled with aberrant gene methylation 
(Bardhan & Liu 2013). There are several mechanisms by which the epigenome is modified but 
the most common are DNA methylation and histone modification. These two major 
epigenetic mechanisms play a vital role in the development of CRC and other cancers. These 
processes are not independent, instead they work together to control gene expression and 
therefore tumourigenesis of CRC. 
 
1.6.1 DNA methylation  
DNA methylation is the process by which a methyl group is added to the 5’ position of cytosine 
to produce 5-methyl cytosine leading to methylation of CpG sites. This reaction is catalysed 
by a group of enzymes called DNA methyltransferase (DNMTs: DNMT1, DNMT3a and 
DNMT3b). DNA methylation is an essential process required for mammalian cell survival 
demonstrated by the finding that DNMT mutations result in embryonic lethality (Li et al. 
1992). Aberrant methylation patterns have been strongly linked to CRC tumourigenesis, 
specifically the hypomethylation of oncogenes and hypermethylation of promoter regions of 
tumour suppressor genes such as those involved in DNA repair. Hypermethylation causes 
gene silencing and genome instability as well as altered apoptotic mechanisms, DNA repair 
and cell cycle. (Bardhan & Liu 2013). DNA hypomethylation is involved in CRC tumourigenesis 
through the loss of methylation of the CpG sites of important genes required to maintain 
genomic stability (Bardhan & Liu 2013).  
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1.6.2 Histone modification 
Chromatin is comprised of DNA that is wound around histone proteins and the state of the 
chromatin in a cell controls gene expression. A chromatin conformation that is 
opened/relaxed allows transcription factors to gain access to bind to promoter regions to 
activate the transcription of genes. However, when the chromatin is in a condensed or closed 
state, it limits the accessibility of transcription factors to bind to promoter regions and 
therefore represses the activation of gene transcription (as illustrated in Figure 5). The 
chromatin is constantly alternating between a relaxed and condensed state (Bardhan & Liu 
2013). Post-translational modifications to the histone proteins in chromatin include 
acetylation, deacetylation, methylation and phosphorylation and these modifications can 
change the chromatin confirmation and therefore gene transcription.  
The process of histone acetylation is controlled by two types of enzymes: histone 
acetyltransferases (HATs) and histone deactylases (HDACs) which regulate the addition or 
deletion of an acetyl group to the lysine residues on the N-terminal tails of histones (Bardhan 
& Liu 2013). The addition of an acetyl group neutralises the lysine’s positive charge and causes 
the histones and DNA to repel against each other resulting in weakened interactions and to 
some extent interactions between neighbouring histones (Roth et al. 2001). These changes 
alter the structure of chromatin which leads to a more open and relaxed formation allowing 
gene transcription to occur (Roth et al. 2001).   The function of HDACs is opposite to HATs and 
involves the removal of the acetyl group from the N-terminal of core histones which re-
instates the positive charge. This enables a stronger association between the histones and 
DNA resulting in a condensed chromatin and as a result transcription factors are denied access 
to the promoters of genes therefore gene expression is blocked  (Bardhan & Liu 2013). HATs 
 | P a g e  
Amanda Dieckmann 
30 
and HDACS are considered transcriptional co-activators and co-suppressors. Imbalances 
between HATs and HDACs plays an important role in the inactivation of transcriptional factors 
resulting in the epigenetic silencing of tumour suppressors therefore contributing to CRC 
tumourigenesis.  
Histone methylation is another essential post-translational modification of histones and helps 
to regulate gene expression via the addition or removal of methyl groups to lysine and 
arginine residues on the N-terminal tails. The balance between histone methylation and 
demethylation is controlled by two groups of enzymes named histone methyltransferases 
(HMTases) and histone demethylases (HDMs) (Bardhan & Liu 2013). A disruption in histone 
methylation homeostasis can lead to tumourigenic changes. Overexpression of the HMTase 
Euchromatic Histone Lysine Methyltransferase 2 (Ezmt2) has been associated with CRC and 
other cancers as it is directly involved in cell proliferation (Cho et al. 2011; Gonzalez et al. 
2009; Natarajan et al. 2010; Yu et al. 2007). 
Histone phosphorylation involves the addition of a phosphate group to serine residues (Cohen 
et al. 2011), relaxing the binding of DNA to histones and  allowing transcription of genes within 
the affected region (Dou & Gorovsky 2002). Histone phosphorylation has also been associated 
with a number of vital cellular processes such as transcriptional activation, mitosis, meiosis, 
DNA damage repair and apoptosis and therefore aberrant expression of histone 
phosphorylation enzymes has been linked to tumourigenesis (Cohen et al. 2011).     
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Figure 5: Conformation of chromatin controls gene expression as it regulates accessibility of 
transcriptional factors to bind to promoter regions to initiate gene transcription (modified 
from Greco & Condorelli 2015). 
 
1.7 Dietary interventions as potential anti-CRC agents 
Curcumin is a polyphenol, extracted from the rhizomes of Curcuma longa (turmeric) plant and 
has long been considered an important therapeutic agent in both Indian and Chinese 
medicine, which may account for the lower incidence of CRC in these countries.  Curcumin is 
relatively inexpensive to produce and has shown promising pharmacological potential 
demonstrating anti-inflammatory, antineoplastic, antioxidant and chemopreventative 
properties (Hardy & Tollefsbol 2011). Numerous studies have also demonstrated low toxicity 
of curcumin with a number of dose escalation clinical trials establishing the safety of curcumin 
even at high doses of 12 grams per day (Patel et al. 2010). Cancer cells that have been treated 
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with curcumin have demonstrated characteristics similar to apoptotic cells, with curcumin 
interfering with a number of cell signalling pathways, such as EGFR, resulting in cell death 
(Starok et al. 2015).  
In CRC studies using animal models, curcumin has been shown to supress tumour activity 
through downregulation of EGFR expression resulting in the inhibition of growth in neoplastic 
(abnormal) cells (Chen & Xu 2005; Chen et al. 2006). Curcumin exerts its effects on EGFR via 
two pathways, the first is the reduction in intrinsic kinase activity and the second is the EGF-
mediated phosphorylation of the receptor which prevents the binding of ligands to the 
receptor. Curcumin not only targets EGFR but also the HER2 resulting in decreased tyrosine 
kinase activity of this receptor as well, which is important as activation of EGFR commonly 
involves formation of heterodimers with HER2 (Patel et al. 2010). Curcumin also further 
impacts EGFR and HER2 expression as it inhibits transcription of these genes by inhibiting 
early growth response protein gene 1 (Egr-1) ( Chen et al. 2006; Singh et al. 1996), which is a 
nuclear phosphoprotein that binds to GC-rich sequences within promotor regions of genes 
involved in the regulation of other gene expression, including EGFR (Chen et al. 2006).   
Curcumin has also been shown to target another key hallmark of cancer, angiogenesis, that is 
the formation of new blood vessels. The migration, proliferation and differentiation of human 
vascular endothelial cells (HUVEC) promotes angiogenesis (Patel et al. 2008) and curcumin 
has been found to inhibit the proliferation of HUVEC and human vascular smooth muscle cells 
(HVSMC) causing the suppression of vascular tubule formation (Singh et al. 1996). Curcumin 
has also demonstrated an ability to sensitise cancer cells to chemotherapy treatment. Recent 
clinical trials administering curcumin in combination with cytotoxic chemotherapy agents 5-
fluorouracil and oxaplatin resulted in a greater apoptotic response and growth inhibition of 
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cancer cells when compared to chemotherapy treatment alone (Patel et al. 2008). Unlike 
many other therapeutic agents involved in cancer treatment, curcumin appears to only target 
cancer cells whilst sparing its cytotoxic effects on normal healthy cells (Aggarwal et al. 2006), 
further adding to its potential as a therapeutic agent for treating not only CRC but many other 
cancers. The effect of curcumin on actually preventing high fat diet-induced CRC has not been 
published.  
Using an established male Wistar rat obesity model (Panchal & Brown, 2010), this study has 
investigated the effects of a diet high in simple carbohydrates and animal fat (HCHF) on the 
gene expression of CRC tumourigenic markers, ADAM17, EGFR and TGFα and epigenetic 
modifying enzymes in both the proximal and distal colon. It has also investigated the effect of 
curcumin in preventing any of these molecular changes due to the HCHF diet. The hypothesis 
was that curcumin could prevent the CRC gene expression changes in the HCHF rats to that 
exhibited in the colons of rats fed a normal corn starch diet.  
The aims of this study were to investigate:  
1. The expression of CRC biomarkers EGFR, ADAM17 and TGFα in the proximal colon and 
distal colon of rats fed either a HCHF diet or a corn starch diet for 16 weeks or a HCHF 
diet for eight weeks followed by a corn starch diet for another eight weeks; 
2. The effects of supplementing 100 mg/ kg mass of curcumin on the expression of CRC 
biomarkers in the colons of rats fed a HCHF diet or a corn starch diet for 16 weeks; 
and 
3. The difference in expression of epigenetic modifying enzymes in the proximal and 
distal colons of rats fed a HCHF diet or a corn starch diet for 16 weeks.  
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Chapter 2: Materials and Methods   
 
2.1 High fat and high carbohydrate rat model 
Colon tissue samples were collected from a total of fifteen male Wistar rats that were being 
used for other experiments under USQ ethics approval (15REA008) and in accordance with 
the re-use of animal tissues principle of the Australian Code for the Care and Use of Animals 
for Scientific Purposes 8th edition (2013). Twelve rats were generously provided by Jessica 
Pahl and Ryan Du Preez after these researchers had removed tissue for their experiments. 
Three of these rats had been on a control standard corn starch diet (CS), three on a high 
carbohydrate and high fat diet (HCHF), three on the control corn starch diet supplemented 
with 100 mg/kg body mass of curcumin (C-100) and three on the high carbohydrate and high 
fat diet supplemented with 100 mg/kg body mass of curcumin (H-100). The additional three 
rats had been fed a HCHF diet for the first eight weeks and then changed to a CS diet for the 
final eight weeks of their treatment and these rats were generously provided by Dr Sunil 
Panchal and Dr Stephen Wanyonyi after they had removed tissue for their experiments. A 
total of five different diets were investigated: CS (control standard diet), HCHF (treatment 
diet), CS diet combined with dietary intervention curcumin at 100 mg/ kg body mass (control 
for the effect of curcumin), HCHF with curcumin at 100 mg/ kg body mass (treatment with 
intervention diet) and finally HCHF administered for eight weeks and then reversed back to 
CS diet for remaining eight weeks (H8C8) (the dietary compositions are described in Table 1). 
Rats were eight weeks old when they were started on the diet protocol, with interventions 
introduced after eight weeks. Rats remained on protocol for a total of 16 weeks and 
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euthanised via an intraperitoneal injection of pentobarbitone sodium (Lethabarb, Virbac) at 
a dose of 100 mg/kg. Prior to euthanising, each rat was weighed and their mass recorded.  
Table 1: Diet protocols and sample size 
CS diet (7% fat): 570 g of cornstarch, 155 g of 
powdered rat food (Specialty Feeds, Glen Forest, Western 
Australia), 25 g of Hubble, Mendel, and Wakeman salt 
Mixture and 250 g of water per kilogram of diet; n=3 
HCHF diet (24% fat): 175 g of fructose, 395 g of sweetened condensed 
milk, 200 g of beef tallow, 155 g of powdered rat food, 25 g of 
Hubble, Mendel and Wakeman salt mixture, and 50 g of water 
per kilogram of diet. Drinking water supplemented with 25% fructose; n=3 
Control curcumin diet: CS diet 8 weeks, CS (as above) +100 mg/kg body mass curcumin 8 
weeks; n=3 
HCHF curcumin diet: HCHF diet (as above) 8 weeks, HCHF (as above) + 100 mg/kg body mass 
curcumin 8 weeks; n=3 
H8C8 diet: HCHF diet 8 weeks, CS diet 8 weeks; n=3 
 
 
2.2: Tissue dissection 
Tissue samples were collected on four separate occasions over a two week period. Following 
euthanasia, a section of proximal and distal colon approximately 2.5 cm in length was 
dissected from each rat and immediately placed in liquid nitrogen. Approximately half of the 
sample was transferred into a 1.5 mL microfuge tube for protein extraction as outlined in 2.7. 
A needle punch biopsy was performed on the remaining sample and these tissue fragments 
16 weeks  
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(representative of different locations in the colon) were transferred into a 1.5 mL microfuge 
tube and homogenised using a 25 gauge needle and 1 mL syringe in 600 µl of RLT lysis buffer 
(Qiagen). Samples were stored at -80°C prior to RNA extraction.  
 
2.3 RNA extraction and quantification  
Total RNA was extracted from tissue samples following the manufacturer’s protocol from a 
commercially available RNA extraction kit (Qiagen RNAeasy Mini kit). The exact components 
of the buffers are commercial in confidence. Briefly, 700 μl of each sample was transferred 
onto Qiagen QIAshredder columns (Qiagen) and centrifuged at 12 k rpm for one minute. 
Samples were then transferred onto spin columns and centrifuged for a further 15 seconds at 
10 k rpm. 700 μl of RW1 wash buffer (Qiagen) was then added to each column and then 
centrifuged again at the same speed and length of time (15 seconds at 10 k rpm). Following 
this step, 500 μl of RPE extraction buffer (Qiagen) was added and column was centrifuged for 
15 seconds at 10 k rpm. Another 500 μl of RPE buffer was added to the column which was 
then centrifuged for two minutes at 10 k rpm. The column was then placed in a new 1.5 mL 
collection tube and 40 μl of RNase free water was added directly to the membrane and then 
centrifuged for one minute to elute the RNA. The concentration of RNA was then determined 
using a Nano Drop (Thermo Scientific).  
 
2.4 cDNA synthesis  
Complementary DNA (cDNA) synthesis was performed using the Bio-Rad iScript cDNA 
synthesis kit, according to the manufacturer’s instructions on 1 µg of RNA to produce a total 
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volume of 20 µl cDNA. The kit included both random hexamer primers and oligo(dT) primers. 
The incubation conditions used for cDNA synthesis included 25°C for five minutes, 46°C for 20 
minutes and 95°C for one minute. The cDNA produced was then used as the template for real 
time reverse transcription polymerase chain reaction (RT-PCR).  
 
2.5 Real time reverse transcription polymerase chain reaction (RT-qPCR) 
2.5.1 EGFR pathway analysis  
PCR master mixes were prepared for each PrimePCR assay (Bio-Rad) EGFR, ADAM17, TGFα 
and beta actin by combining primers, SYBR Green master mix (Bio-Rad) and RNase-free water 
according to the Bio-Rad real time RT-PCR protocol. A total of 9 µl of the appropriate master 
mix was aliquoted into each well. One µl of cDNA from each control or treatment group or 
RNase-free water (no template control) was added to the master mix and reactions were 
performed in triplicate. The plate was then subjected to 40 cycles of PCR using a Bio-Rad CFX-
384 Touch Thermocycler. Cycle thresholds (Cts) for each cDNA/primer combination were 
determined by the Bio-Rad CFX Manager and Qbase PLUS software.    
The primer sequences for the PrimePCR assays (Bio-Rad) were not provided by the supplier 
however the chromosome locations of the amplicons are listed in Table 2. Each assay was 
validated by Bio-Rad and this data is available on the web site (see http://www.bio-
rad.com/en-au/prime-pcr-assays/assay/qrnocid0056984-primepcr-sybr-green-assay-actb-
rat). The house-keeping gene beta actin was designed to be intron-spanning so that the melt 
curve analysis could be used to ensure that there was no genomic DNA contamination. 
Genomic contamination would be indicated by two peaks. 
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Table 2: Information on the Bio-Rad PrimePCR assays used for SYBR Green real time gene 
expression analysis. 
Primer Target Unique Assay ID Chromosome Location  
EGFR qRnoCID0008508 14:100442581-10044463 
ADAM17 qRnoCID0004148 15:53225651-53226718 
TGFα qRnoCID0006255 4:182534498-182603831 
Beta actin  qRnoCID0056984 12:15745866-15746909 
 
2.5.2 Epigenetic modification real time PCR analysis  
Primers for eighty-four genes which encode for enzymes involved in epigenetic modification 
were pre-dried on a 384 well PrimePCR pathway epigenetic chromatin modification enzyme 
analysis plate (Bio-Rad). The functions of the genes analysed included DNA methylation and 
histone acetylation, methylation and phosphorylation. Five housekeeping genes were also 
included for normalisation of expression. The PCR mastermixes were prepared consisting of 
cDNA pooled from three rat colons (either distal CS, distal HCHF, proximal CS or proximal 
HCHF), SYBR green and RNase free water, then 9.5 μl of each mastermix was added into each 
well. The plate was then subjected to 40 cycles of PCR using a Bio-Rad CFX-384 Touch. 
Threshold cycles (CTs) for each cDNA/primer combination were determined by the Bio-Rad 
CFX Manager and Qbase PLUS software.    
 
2.6 Relative gene expression (CT) analysis  
Threshold cycle (CT) values obtained from the Qbase PLUS software were used to calculate 
changes in expression using the delta delta (ΔΔ) CT data analysis method. For each target, ΔCT 
value was calculated by normalising the expression of the target gene (such as EGFR) with the 
reference or housekeeping gene (beta actin). Then ΔΔCT was calculated by using the formula 
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ΔCT (treatment/HCHF/intervention cDNA) – ΔCT (control/CS cDNA). Finally, the fold change 
in target gene expression was calculated using this formula 2-ΔΔCT (Rao et al. 2013).  
 
2.7 Protein Extraction  
During tissue extraction approximately half of the sample was dissected into small sections 
and placed in a 1.5 mL microfuge tube containing 1 mL of radioimmunoprecipitation (RIPA) 
lysis buffer (0.2% Triton X-100; 0.1% sodium deoxycolate; 0.1% SDS; 1M NaCl; 1M Tris 
supplemented with 1% Thermo Scientific Halt protease and phosphatase inhibitors). Samples 
were homogenised using short bursts of sonication. To prevent the denaturation of protein, 
samples were placed on ice intermittently during sonication. Once homogenised, samples 
were then placed on ice on an orbital shaker for two hours. Samples were then centrifuged 
for 20 mins at 12,000 X g at 4°C and supernatants were collected. The concentration of protein 
samples were then determined by performing a BCA assay (Thermo Scientific) following the 
manufacturer’s instructions.  
 
2.8 Polyacrylamide gel electrophoresis (PAGE) 
Due to the size of the EGFR protein, an 8% bisacrylamide SDS separating and 4% stacking gel 
was used to analyse this protein. Five μL of 5x Laemmli SDS loading buffer was added to the 
protein samples and a positive control of EGFR-containing lysate before they were heated to 
95°C, cooled and then loaded into the gel. Electrophoresis was performed for one hour at 160 
volts.  
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2.9 Western immunoblot  
After PAGE, proteins were transferred onto nitrocellulose membranes using a transblot 
apparatus (Thermo Scientific) overnight at 10 volts, and 4°C. Membranes where then 
incubated in blocking buffer (5% skim milk powder in tris-buffered saline, 0.1% Tween 20; 
TBST buffer) for one hour at room temperature on an orbital shaker. Membranes were then 
incubated with a monoclonal mouse anti-human EGFR antibody (1:1000 dilution; Precision 
Antibodies) in blocking buffer overnight at 4°C. Membranes were then washed and incubated 
in an anti-mouse horse radish peroxidase (HRP) conjugated secondary antibody (1:10000 
dilution) in blocking buffer. Bands were detected using a Pierce enhanced chemiluminescence 
(ECL) detection reagent (Thermo Scientific) and imaged by a Fusion Fx digital imager.  
 
2.10 Statistical analysis of real time RT-PCR results 
Fold changes in the gene expression for each target in the colons of rats fed a HCHF diet and 
interventions compared to those fed a CS diet were derived from the 2-ΔΔCT calculations. The 
statistical significance of these fold changes was analysed using one way ANOVA and Tukey 
Post Hoc test (SPSS, IBM). 
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Chapter 3: Results 
 
3.1: Effect of diet on body mass 
As expected, after 16 weeks on a HCHF diet, rats were significantly heavier than rats fed a CS 
diet (p value = 0.002) and rats in the H8C8 diet group (p value = 0.009), suggesting that 
reverting back to a CS diet can reduce body mass after only eight weeks. Interestingly no 
significant difference was seen between the HCHF diet and the HCHF diet with curcumin 
intervention (H-100 mg curcumin) or the CS diet and the CS diet with curcumin intervention 
(C-100 mg curcumin) suggesting that curcumin doesn’t affect body mass.   
 
Figure 6: Final body mass was significantly higher in HCHF compared to CS (a vs b p-value = 
0.002). Curcumin did not significantly change the body mass of either CS or HCHF rats (p-
value> 0.05). H8C8 significantly reduced body mass compared to HCHF (b vs e p-value= 0.009). 
No significant difference between control curcumin and H8C8 compared to CS (a vs c p-
value=0.11, a vs e p-value = 0.84).  
 
3.2: HCHF diet upregulates the expression of EGFR, ADAM17 and TGFα  
In order to determine whether a HCHF diet could upregulate the expression of the CRC 
biomarkers EGFR, ADAM17 and TGFα gene expression fold change was determined using real 
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time RT-PCR, CT analysis and 2-ΔΔCT. Figures 7 - 9 demonstrate that the HCHF diet significantly 
increased the expression of EGFR, ADAM17 and TGFα and in the distal colon of rats, therefore 
suggesting that HCHF diet upregulates the expression of CRC biomarkers in distal colon after 
only 16 weeks. Unlike the distal colon, no statistically significant difference was observed for 
any of the CRC biomarkers in the proximal colon although there was a trend towards an 
increase in CRC biomarker expression (Figures 10 – 12).  
 
3.3 Dietary interventions prevent the high expression of CRC biomarkers due to the HCHF 
diet 
3.3.1 Curcumin  
Curcumin was hypothesised to be an effective therapeutic agent for preventing HCHF diet 
induced CRC biomarker gene expression.  As demonstrated in Figure 7, there was a ten-fold 
decrease in the expression of EGFR in the distal colon in response to the addition of curcumin 
to the HCHF diet. The addition of curcumin to the HCHF diet also led to a three-fold reduction 
in the expression of ADAM17 in the distal colon (Figure 8). Interestingly curcumin did not 
appear to have the same effect on EGFR and ADAM17 in the proximal colon, with no 
significant changes in expression observed between HCHF and H-100mg curcumin groups 
(Figures 10 and 11). Curcumin also did not appear to alter the expression of TGFα in proximal 
or distal colon (illustrated in Figures 9 and 12).  No significant difference was seen between 
CS group and C-100mg curcumin group for any of the targets suggesting that curcumin 
doesn’t lead to tumourigenic changes in the colon of rats fed a normal diet (Figures 7 – 12).  
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3.3.2 H8C8  
To evaluate the effects of reverting from a HCHF diet back to a normal CS diet on the 
expression of the CRC biomarkers, rats were fed a HCHF diet for eight weeks and the changed 
to CS diet for the final eight weeks of the protocol. EGFR, ADAM17 and TGFα expression was 
significantly decreased in the distal colons in H8C8 group compared to HCHF group (Figures 
7, 8 and 9) suggesting that reverting back to a normal diet after eight weeks on a HCHF diet is 
effective in reversing tumourigenic changes caused by HCHF diet in the distal colon.  
 
 
 
 
 
 
 
 
 
Figure 7: mRNA fold change expression of distal colon EGFR compared to CS HCHF 
diet significantly increased EGFR expression in distal colon (a vs b p-value=0.001). 
Curcumin significantly reduced expression of EGFR compared to HCHF (b vs c p-
value=0.001, b vs d p-value=0.001). H8C8 also significantly reduced EGFR expression 
compared to HCHF (b vs e p-value=0.001). No significant increase in expression of 
EGFR between control and treatments (p-value>0.05).  
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Figure 8: mRNA fold change expression of distal colon ADAM17 compared to CS. HCHF 
diet significantly increased ADAM17 expression in distal colon (p-value= 0.005). 
Curcumin significantly reduced expression of ADAM17 compared to HCHF (b vs d p-
value=0.004).H8C8 also significantly reduced ADAM17 expression compared to HCHF 
(b vs e p-value=0.035). No significant increase in expression of ADAM17 between 
control and treatments (p-value>0.05).  
Figure 9: mRNA fold change expression of distal colon TGFα compared to CS. HCHF diet 
significantly increased TGFα expression in distal colon (a vs b p-value= 0.039). Curcumin 
did not significantly reduce expression of TGF⍺ compared to HCHF (b vs d p-value=0.6) 
.H8C8 also significantly reduced TGFα expression compared to HCHF (b vs e p-
value=0.035). No significant increase in expression of TGFα between control and 
treatments (a vs c p-value= 0.9 and a vs e p-value=0.8).  
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Figure 10: mRNA fold change expression of proximal colon EGFR compared to CS. One way 
ANOVA p-value=0.5698, Tukey post hoc: no significant difference between any test samples 
all p-value> 0.05. 
Figure 11: mRNA fold change expression of proximal colon ADAM17 compared to CS. One 
way ANOVA p-value=0.4796, Tukey post hoc: no significant difference between any test 
samples all p-value> 0.05. 
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Figure 12: mRNA fold change expression of proximal colon TGFα compared to CS One way 
ANOVA p-value=0.7463, Tukey post hoc: no significant difference between any test samples 
all p-value> 0.05.5. 
 
3.4 Dietary induced epigenetic changes  
Analysis of diet-induced epigenetic modifications was conducted by measuring the expression 
of 84 key enzymes known to stimulate epigenetic changes. As illustrated in Figures 13 and 14, 
the expression of epigenetic modification enzyme genes in the distal and proximal colons 
from HCHF rats differed from the expression pattern seen in the CS rat colons. In the distal 
colon of HCHF rats, there was an increase in the genes that code for enzymes involved in DNA 
methylation (Dnmt3a), histone phosphorylation (AURKB) and histone methylation (Ehmt2) 
and a decrease in the expression of histone deacetylases (HDAC1 and HDAC7) and another 
histone methylation enzyme gene (Symd3) (Figure 13). Analysis of the proximal tissue showed 
an increase in the expression of genes that code for enzymes associated with histone 
acetylation (CIITA) and a decrease in the expression of genes involved in histone methylation 
(Suv39h1, Suv39h2, Suv420h2 and Ezh2) (Figure 14).  
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Figure 13: Fold –changes in mRNA expression of epigenetic modification enzyme genes in the distal 
colons of rats in response to HCHF diet (compared to corn starch diet). Samples representative of 
pooled cDNA from three rats in each group. 
Figure 14: Fold –changes in the mRNA expression of epigenetic modification enzyme genes in 
the proximal colons of rats in response to HCHF diet (compared to corn starch diet). Samples 
representative of pooled cDNA from three rats in each group. 
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3.5 Dietary induced changes in the protein levels of EGFR  
Western immunoblot was used to determine whether the changes in gene expression 
revealed by real time RT-PCR were also occurring at the protein level. Protein lysates were 
prepared from the colons of rats fed the CS, HCHF and intervention diets and protein levels 
of EGFR and beta-actin were investigated. Due to time constraints, a successful result was not 
achieved and further optimisation is required.  
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Chapter 4: Discussion  
 
The impact of colorectal cancer is a global concern and more effective strategies for 
preventing the disease are urgently required. Increased rates of sporadic CRC have been 
strongly linked to the Western diet and lifestyle, that is consuming a diet that is high in simple 
carbohydrates, high in animal fats and low in dietary fibre as well as physical inactivity (Schulz 
et al. 2014). As diet is a modifiable risk factor for CRC tumourigenesis this study sought to 
determine whether the short term consumption of a high animal fat and high simple 
carbohydrate diet could stimulate the molecular pathways that commonly drive sporadic 
CRC. It also investigated whether dietary interventions of either curcumin or reverting back 
to a balanced diet could protect the colon from these molecular changes. A rat model was 
used to demonstrate that the Western diet can significantly increase the mRNA expression of 
EGFR, ADAM17 and TGFα which are established molecular drivers of CRC. This effect was only 
statistically significant in the distal colon which is in congruence with the finding that EGFR 
overexpression is more common in colon cancers located in the distal colon. Although 
curcumin has been previously investigated as a treatment for established colon cancer, 
according to the published literature this is the first study to demonstrate that curcumin could 
have a protective effect in normal colon tissue by preventing the up-regulation of EGFR and 
ADAM17. This study also provided preliminary evidence that a diet high in animal fats and 
simple carbohydrates could be driving gene expression changes via epigenetic modifications.  
The overexpression of EGFR has been reported to occur in up to 85% of sporadic, that is, non-
hereditary CRC cases (Ellina et al. 2014). There is also a significantly higher frequency of EGFR 
over-expression and amplified EGFR signalling in tumours located in the distal colon 
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compared to tumours located in the proximal colon (Missiaglia et al. 2014). This study also 
demonstrated that EGFR expression was significantly higher in the distal colon compared to 
the proximal colon of rats fed the HCHF diet.  
Genetically modified mouse models designed to induce CRC tumourigenesis have been 
primarily used to investigate the role of EGFR and diet. Dougherty et al (2009) demonstrated 
the relationship between EGFR and high fat diet-induced CRC, using a mouse model that had 
been genetically manipulated to lose 90% of its EGFR function. These EGFR knockdown mice  
displayed a significantly lower CRC tumour incidence and number of CRC tumours per animal 
compared to those with normal functioning EGFR despite being fed the same high fat diet for 
40 weeks (Dougherty et al. 2009). This study utilised colon samples from a genetically 
unmodified (wildtype) rodent model administered a HCHF diet (more representative of the 
Western diet than high fat alone) for a time period of 16 weeks. The study demonstrated a 
significant fold change increase in the distal colon mRNA expression of EGFR. According to the 
literature, this is the first study to demonstrate a significant increase in EGFR mRNA 
expression in the colon in response to HCHF diet in a genetically normal rat. These findings 
further support the role of EGFR in driving high fat diet-induced CRC development in the distal 
colon.  
The mRNA expression of both ADAM17 and TGFα was also significantly increased in the distal 
colons of rats fed a HCHF diet compared to rats fed a corn starch diet. ADAM17 is a more 
recent target that has been associated with CRC tumourigenesis. It’s normal role in the colon 
is to regulate colonic epithelial cell proliferation and differentiation through the proteolytic 
shedding of EGFR pro-ligands such as TGFα (Shimoda et al. 2016). Once released from the cell 
membrane, TGFα binds to EGFR to initiate downstream signalling cascades leading to 
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increased cellular proliferation and differentiation (Shimoda et al. 2016). Blanchet-Jossic et al 
(2005) reported the up-regulation of ADAM17 mRNA in 90% of CRC tumours investigated 
along with the up-regulation of EGFR mRNA in 77% of these tumours (Blanchet-Jossic et al. 
2005). More evidence to support the role of ADAM17 in diet-induced CRC tumourigenesis 
was published recently by Mustafi et al (2016) who reported that a high fat diet administered 
for 40 weeks significantly up-regulated the mRNA expression of ADAM17 in CRC tumours in a 
mouse model. Furthermore, the targeted deletion of ADAM17 within the colonic epithelial 
cells significantly decreased tumour incidence, further supporting a role for ADAM17 in diet-
induced CRC (Mustafi et al. 2016).  
It had previously been reported that a high fat diet (20% fat) for 40 weeks increased TGFα 
mRNA expression in CRC (Dougherty et al. 2009; Mustafi et al. 2016), however the present 
study demonstrated that HCHF diet increased TGFα mRNA after only 16 weeks. This suggests 
that tumourigenic changes are potentially occurring in a much shorter time period than 
previously reported. As ADAM17 can shed TGF from its membrane-bound precursor 
proTGF it can be speculated that the increase in ADAM17 increased the bioavailability of 
TGF which when bound to EGFR triggers downstream signalling cascades and further up-
regulation of TGFα gene expression. 
Curcumin as a dietary intervention has shown therapeutic potential as an anti-inflammatory, 
antineoplastic, antioxidant and chemopreventative agent (Patel et al. 2008). The effects of 
curcumin on EGFR expression in CRC cells has been investigated in both animal models and 
human cell culture. Multiple studies have demonstrated that curcumin inhibits CRC through 
a dual mode of action that targets both the inhibition of receptor tyrosine activity and 
suppression of gene expression involved in the activation and transcription of EGFR (Chen & 
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Xu 2005; Chen et al. 2006; Starok et al. 2015). Despite its extensive investigation as a CRC 
treatment, there was no published study that demonstrated curcumin to have a protective 
effect against diet-induced up-regulated EGFR expression in the colon.  
Results from this study demonstrated that supplementing the HCHF diet with 100 mg/kg body 
mass of curcumin prevented the increase in mRNA expression of EGFR induced by the HCHF 
diet. Interestingly there was no effect on TGFα mRNA expression, suggesting that TGF 
expression may be resistant to the effects of curcumin. Overexpression of TGF has been 
associated with resistance to anti-EGFR therapy, with the overexpression of TGF shown to 
induce EGFR-MET interactions. MET, also known as Hepatocyte Growth Factor Receptor, is a 
cell membrane tyrosine kinase receptor and aberrant expression is linked to a number of 
cancers including CRC (Cecchi et al. 2012; Di Renzo et al. 1995). Dysregulation of MET 
signalling has been implicated as one of the main pathways in which growth inhibition by anti-
EGFR drugs can be bypassed. EGFR ligands such as TGF can transactivate MET by inducing 
the formation of heterodimers with members from the EGFR family in the absence of MET 
specific ligands. As a result, anti-EGFR induced growth inhibition is overcome by activating 
both EGFR and MET signalling cascades, which stimulates numerous cellular processes 
involved in cancer progression. Down-regulation of TGF expression using siRNAs has been 
shown to re-sensitise colon cancer cells to anti-EGFR therapy and therefore combining anti-
EGFR drugs with TGF or MET inhibitors could be considered to improve treatment response 
(Troiani et al. 2013).  
Results from this study also demonstrated that curcumin was effective in preventing the 
increase in mRNA expression of ADAM17 caused by the HCHF diet in the distal colon. This is 
the first study to investigate the effects of curcumin on the expression of ADAM17 in the colon 
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and therefore the mechanism by which this occurs is unknown. Another mechanism that may 
explain why curcumin prevented the HCHF-stimulated increase in mRNA expression of 
ADAM17 and EGFR but not TGFα may be that curcumin is exerting its effect through the 
inhibition of Nuclear Factor kappa B (NF-κB). NF-κB has been shown to play an important role 
in both the maturation of ADAM17 and activation of EGFR but with no evidence of its 
involvement in TGF a functionality.  In order for NF-κB activation to occur, proteolytic 
degradation of IkBa is required. A study by Pendurthi et al (1997) demonstrated that curcumin 
prevents the degradation of IkBa and therefore prevents the subsequent activation of NF-κB 
(Pendurthi et al. 1997).  
NF-κB has been identified as a key regulator of ADAM17, as it is required for the maturation 
of ADAM17 from its pro-form and subsequent activation. Inhibition studies using NF-κB 
inhibitor demonstrated that inhibition of this protein resulted in suppression of ADAM17) 
expression (Takamune et al. 2008). Multiple studies have suggested that EGFR and NF-κB 
work together to produce an environment that promotes tumour development and 
progression via sustained cell proliferation, survival and invasion (Biswas and Iglehart, 2006; 
Habib et al. 2001 and Sordella et el. 2004). The activation of EGFR and NF-κB are inter-related 
with growth factors such as EGF linked to activation of NF-κB when bound to EGFR. EGF 
activates NF-κB via the IkB kinase complex. Targeted genes involved in activation of NF-κB 
such as KIAA1199 and IkBα and IkB have been shown to display feedback mechanisms that 
impact on EGFR-dependent signaling pathways in a number of cancer types. In cervical cancer 
KIAA1199 (which is activated by NF-κB) has been shown to reduce cell death by stimulating 
EGFR phosphorylation activating downstream singling cascades that promote cell survival and 
also stimulates EGF-dependent epithelial mesenchymal transition thereby promoting 
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migration and invasion (Shostak et al. 2014). In head and neck cancers knockdown of IkBα 
and/or IkB both of which are required for NF-κB activation, resulted in significantly reduced 
levels of EGFR mRNA and protein expression (Nottingham et al. 2014).  
Based on current knowledge and the results of the experiments presented here it is plausible 
to hypothesise that curcumin is preventing the increase in ADAM17 and EGFR mRNA in 
response to HCHF diet through the suppression of NF-κB activation. Currently there is no 
known association between NF-κB and TGFα expression and therefore it is expected that 
inhibition of NF-κB would not affect the expression of TGFα, which is supported by the results 
of this experiment.  
Due to its promising response, further investigation is required to determine how curcumin 
is exerting its inhibitory effect on ADAM17 mRNA expression. In addition to its function in 
activating EGFR and numerous EGFR ligands, ADAM17 has been implicated in CRC 
pathogenesis as a stimulator of tumour migration and angiogenesis both of which have been 
classified as hallmark characteristics of CRC (Hanahan and Weinberg, 2000). Inhibition of 
ADAM17 leads to a reduction in the formation of HUVEC blood vessel-like structures (Göőz et 
al. 2009).  Göőz et al (2009) also proposed that ADAM17 stimulates blood vessel formation 
through the activation of matrix metalloprotease 2 (MMP-2) (Göőz et al. 2009). Previous 
studies have demonstrated that curcumin has an inhibitory effect on the formation of new 
blood vessels using HUVEC and HVSMC models and therefore inhibits angiogenesis, which is 
an essential requirement for tumourigenesis (Patel et al. 2010; Singh et al. 1996).  
Curcumin has been extensively studied in a number of research and clinical studies and 
proven to be a safe compound (Cheng et al. 2001; Lao et al. 2006; Shoba et al. 1998) therefore 
adding to its attractiveness as a preventative agent to reduce risk of diet-induced CRC. Based 
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on these findings and the literature demonstrating the safety of curcumin, there is potential 
for curcumin to be an effective preventative agent to reduce HCHF diet-induced 
overexpression of EGFR and ADAM17. 
In addition to investigating the effects of the HCHF diet on CRC biomarkers, this study also 
explored the effects of HCHF diet on the mRNA expression of epigenetic modifying enzymes 
in the distal and proximal colon. The distal colon of HCHF rats showed an increase in the 
expression of the histone phosphorylation enzyme, AURKB, the histone methyltransferase 
enzyme Ehm2 and the DNA methylation enzyme Dmnt3a. Previous studies exploring the 
epigenetic modifications that can occur in the colon in response to a HCHF diet have also 
shown an increase in these targets (Cho et al. 2011; Robertson et al. 1999; Weis et al. 2015). 
The aberrant expression of these enzymes has been implicated in carcinogenesis (Cho et al. 
2011; Robertson et al. 1999; Weis et al. 2015). The dysregulation of AURKB is associated with 
mitotic abnormality and errors in chromosomal formation resulting in instability (Fu et al. 
2007; Ota et al. 2002). This instability can potentially lead to tumourigenic changes in the 
colon via the CIN pathway, which is the most common molecular pathway in sporadic CRC  
(Hagland et al. 2013). Ehmt2 stimulates cellular proliferation and when this mRNA was 
inhibited via small interfering RNAs it led to a decrease in bladder cancer cell growth and 
caused apoptotic cell death (Cho et al. 2011). In the present study, Ehmt2 increased in 
response to the HCHF diet which suggests that this could be a potential mechanism by which 
diet drives CRC tumourigenesis.   Increased expression of Dnmt3a has also been associated 
with widespread regional hypermethylation resulting in the suppression of tumour 
suppressor genes (such as APC) enabling tumourigenic changes to occur within the colon 
(Weis et al. 2015). Dnmt3a is highly expressed in CRC and the targeted deletion of this gene 
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can inhibit tumour growth (Weis et al. 2015). Dnmt3a is involved in a number of cellular 
mechanisms implicated in tumourigenesis including cell growth, cell proliferation, cell survival 
and inhibition of cell death (Robertson et al. 1999; Weis et al. 2015). The present study has 
shown that the HCHF diet increased the expression of Dnmt3a, therefore suggesting that one 
of the multiple pathways of HCHF diet-induced CRC, might arise through the increased 
expression of Dnmt3a in the distal colon resulting in the suppression and inactivation of a 
number of tumour suppressor genes which would usually control tumourigenic changes in 
the colon.  
In the distal colon, a reduction in the expression of Symd3 and HDACs 1 and 7 was also 
observed. Symd3 is a histone methyltransferase and is referred to as a proto-oncogene as it 
has a functional role in the activation of transcriptional regulators associated with cell 
proliferation, epithelial-mesenchymal transition and various other oncogenic pathways. 
Overexpression of Symd3 has been implicated as a major driver of CRC and other cancers 
(Sarris et al. 2016). Increased expression of HDACs is also commonly associated with CRC and 
linked to a worse survival compared to tumours with normal expression of HDACs. As a result 
of its function, up-regulation of HDACs has been shown to cause an increase in transcriptional 
silencing of tumour suppressors and therefore increases risk of developing CRC (Bardhan & 
Liu 2013). Due to their important functions in CRC development it was expected that both 
Symd3 and HDAC expression would be increased in response to the HCHF diet, however the 
results showed that these genes were substantially downregulated. This finding requires 
further investigation to determine whether this is an anomaly or whether the increased 
expression of these genes is not involved in diet-induced CRC.   
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In the proximal colon, the HCHF diet led to the up-regulation of the histone acetylation 
enzyme CIITA gene expression and down-regulation in the expression of several histone 
methylation transferases including Suv39h1, Suv39h2, Suv420h2 and Ezh2. The latter group 
of enzymes are involved in transcription repression, gene silencing, cell migration and 
invasion (Ozdag et al. 2006; Yokoyama et al. 2014). CRC is typically associated with 
overexpression of Suv39h1, Suv420h2 and Ezh2, however results from this study have 
demonstrated that HCHF diet leads to reduced expression of these genes compared to the 
corn starch diet. Further investigation is required as this finding only investigated pooled 
samples from three rats in each group.  The finding that Suv39h2 was down-regulated in 
response to the HCHF diet was supported by a published study by Peters et al (2001).  The 
Suv39h2 knock-down mouse experienced chromosomal instabilities that resulted in an 
increased risk of developing CRC tumours demonstrating that Suv39h2 has a protective role 
against CRC tumourigenesis (Peters et al. 2001). The present study showed Suv39h2 to be 
down-regulated in response to the HCHF diet, suggesting a possible link between HCHF diet, 
down-regulated Suv39h2 expression and CRC.   
One of the limitations in the study was the relatively short length of time in which the rats 
were exposed to the diets and treatments when compared to human diets, where the 
majority of humans have been exposed to HCHF diet throughout their entire lifetime or at 
least their adult life.   
The promising results obtained in this study warrants further investigation, especially the use 
of curcumin to prevent the increased expression of EGFR and ADAM17 and potentially the 
risk of developing CRC due to a diet that is high in simple carbohydrates and high in animal 
fat. Moving forward, further investigation into the relationship between HCHF diet and other 
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CRC biomarker expression is required and future studies should determine whether the 
increase observed in mRNA levels is translatable to an increase in protein levels. To 
understand the long term effectiveness of curcumin, experimental studies will need to be 
carried out over a longer period of time. Furthermore, investigation is required into the 
effectiveness of curcumin in ameliorating the expression of other potential biomarkers 
involved in the EGFR/ADAM17 axis, including other EGFR ligands and ADAM10. The 
translation of this research into human patients is the ultimate future study where the effects 
of adding curcumin to the diets of individuals at a high risk of CRC would be explored.   
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Chapter 5: Conclusion 
 
In conclusion, this study has provided preliminary evidence that a diet high in simple 
carbohydrates and animal fats can significantly upregulate the expression of EGFR, ADAM17 
and TGFα in the distal colon after only 16 weeks. As EGFR has been implicated as a major 
driver of CRC tumourigenesis, and increased mRNA expression of ADAM17 and TGFα are also 
common in many CRC tumours, this study proposes that the mechanism of diet-induced CRC 
in the distal colon could be via the up-regulation of these genes. The study has also 
demonstrated that HCHF diet has the potential to cause epigenetic changes via expression 
changes in epigenetic modifying genes in both the distal and proximal colon that may 
potentially drive CRC tumourigenesis independently of EGFR, ADAM17 and TGFα.  
With the continuing increase in CRC incidence coupled with the wide-spread obesity 
epidemic, the global incidence of CRC is projected to increase exponentially with more than 
2.2 million new cases and 1.1 million deaths by 2030 (Arnold et al. 2016). With these alarming 
statistics, new cost effective and safe therapeutic approaches are urgently needed to help 
prevent Western diet induced CRC or at least reduce the risk. Curcumin is an inexpensive and 
safe dietary compound which we demonstrated to prevent the increased expression of 
biomarkers implicated in HCHF induced CRC development and progression.   
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Chapter 7: Appendix   
 
Supplementary Table 1: Body mass 
Sample CS HCHF C-100 H-100 H8C8 
Rat1 412 550 346 515 442 
rat 2 435 514 345 427 432 
rat 3 394 533 373 513 435 
Average 413.67 532.33 354.67 485 436.33 
Standard error 11.865 10.398 9.1712 29.006 2.9627 
 
